NCT01140542View on ClinicalTrials.gov

Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study

PHASE2CompletedINTERVENTIONAL
Enrollment

487

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2008

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Roflumilast

500µg, once daily

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY